Drug Profile
Aminopterin - Syntrix Biosystems
Alternative Names: Aminotrexate; LD-aminopterin; Rac-aminopterinLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator University of Medicine & Dentistry of New Jersey
- Developer Syntrix Biosystems
- Class Antipsoriatics; Benzamides; Glutamates; Pterins; Small molecules
- Mechanism of Action Antimetabolites; Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Psoriasis
- No development reported Precursor cell lymphoblastic leukaemia-lymphoma; Rheumatoid arthritis
Most Recent Events
- 11 Jan 2021 Phase II development for Psoriasis is still ongoing in USA (PO, Tablet) (NCT03431974)
- 11 Jan 2021 Syntrix Biosystems and National Institute of Allergy and Infectious Diseases completes a phase II trial in Psoriasis in USA (PO) (NCT03431974)
- 01 Nov 2018 Phase-II clinical trials in Psoriasis in USA (PO) (NCT03431974)